Reference | </br>1:Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study. Roth T, Black J, Cluydts R, Charef P, Cavallaro M, Kramer F, Zammit G, Walsh J.Sleep. 2017 Feb 1;40(2). doi: 10.1093/sleep/zsw034. PMID: 28364509 </br>2:Dual orexin receptor antagonist, almorexant, in elderly patients with primary insomnia: a randomized, controlled study. Roth T, Black J, Cluydts R, Charef P, Cavallaro M, Kramer F, Zammit G, Walsh J.Sleep. 2016 Oct 10. pii: sp-00223-16. [Epub ahead of print] PMID: 27748238 </br>3:The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems. Parks GS, Warrier DR, Dittrich L, Schwartz MD, Palmerston JB, Neylan TC, Morairty SR, Kilduff TS.Neuropsychopharmacology. 2016 Mar;41(4):1144-55. doi: 10.1038/npp.2015.256. Epub 2015 Aug 20. PMID: 26289145 Free PMC Article</br>4:Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine. Cruz HG, Hay JL, Hoever P, Alessi F, te Beek ET, van Gerven JM, Dingemanse J.Eur Neuropsychopharmacol. 2014 Aug;24(8):1257-68. doi: 10.1016/j.euroneuro.2014.05.002. Epub 2014 May 13. PMID: 24880753 </br>5:Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies. Dingemanse J, Gehin M, Cruz HG, Hoever P.Drug Des Devel Ther. 2014 Apr 28;8:397-403. doi: 10.2147/DDDT.S62118. eCollection 2014. PMID: 24812492 Free PMC Article</br>6:Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant. Hoch M, van Gorsel H, van Gerven J, Dingemanse J.J Clin Pharmacol. 2014 Sep;54(9):979-86. doi: 10.1002/jcph.297. Epub 2014 Apr 21. PMID: 24691844 </br>7:Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J.CNS Drugs. 2014 Apr;28(4):361-72. doi: 10.1007/s40263-014-0150-x. PMID: 24627301 </br>8:Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem. Dingemanse J, Cruz HG, Gehin M, Hoever P.J Pharm Sci. 2014 May;103(5):1548-56. doi: 10.1002/jps.23916. Epub 2014 Mar 6. PMID: 24604243 </br>9:The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats. Morairty SR, Wilk AJ, Lincoln WU, Neylan TC, Kilduff TS.Front Neurosci. 2014 Jan 31;8:3. doi: 10.3389/fnins.2014.00003. eCollection 2014. PMID: 24550767 Free PMC Article</br>10:Validation of an LC-MS/MS method for the quantitative determination of the orexin receptor antagonist almorexant and its four primary metabolites in human plasma. Wagner-Redeker W, Finsterwald I, Dingemanse J.J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Mar 1;951-952:96-103. doi: 10.1016/j.jchromb.2014.01.033. Epub 2014 Jan 30. PMID: 24531213
|